Next Article in Journal
Multi Mycotoxin Determination in Dried Beef Using Liquid Chromatography Coupled with Triple Quadrupole Mass Spectrometry (LC-MS/MS)
Previous Article in Journal
Potential of Cry10Aa and Cyt2Ba, Two Minority δ-endotoxins Produced by Bacillus thuringiensis ser. israelensis, for the Control of Aedes aegypti Larvae
Open AccessArticle

PLA2 Inhibitor Varespladib as an Alternative to the Antivenom Treatment for Bites from Nikolsky’s Viper Vipera berus nikolskii

1
V. N. Karazin Kharkiv University, 61058 Kharkiv, Ukraine
2
Ukrainian Independent Ecology Institute, 61001 Kharkiv, Ukraine
*
Author to whom correspondence should be addressed.
Toxins 2020, 12(6), 356; https://doi.org/10.3390/toxins12060356
Received: 12 August 2019 / Revised: 27 August 2019 / Accepted: 27 August 2019 / Published: 29 May 2020
(This article belongs to the Section Animal Venoms)
Although envenoming by a small East European species of viper is rarely severe, and only exceptionally fatal, lack of specific antivenom stocks in a few areas within this region and possible severe side effects of antivenom application leave most bites to be treated only with antihistamines and supportive therapy. Varespladib is an effective inhibitor of snake phospholipase, and, as such, it could be considered as first-line therapy. The Nikolsky’s viper venom contains an extremely high concentration of phospholipase A2 (PLA2), responsible for the toxic effects of the venom, as well as minor amounts of other toxins. If Varespladib can successfully inhibit PLA2 activity, the Nikolsky’s viper could be one of the first venomous snakes having an antitoxin-specific treatment regimen. To assess that, Varespladib was administered alone subcutaneously to adult male CD-1 mice (8 mg/kg) and compared to mice exposed to Vipera berus nikolskii crude venom (8 mg/kg = 10 LD50) or a combination of Varespladib and the same amount of the venom. Experimental animals were monitored for the presence of envenoming symptoms and mortality for 48 h after injection. Eighty percent of mice receiving both Varespladib and venom survived, while 100% of the control group receiving venom alone died within 4 h. Experimental results are consistent with Varespladib acting as an effective antitoxin in the mouse model against Nikolsky’s viper venom. Further studies are needed under experimental conditions that more closely resemble natural envenoming (i.e., delayed administration). View Full-Text
Keywords: snakebite; Viperidae; therapy; PLA2; inhibitor; Varespladib; mouse snakebite; Viperidae; therapy; PLA2; inhibitor; Varespladib; mouse
Show Figures

Figure 1

  • Supplementary File 1:

    ZIP-Document (ZIP, 7 KB)

  • Externally hosted supplementary file 1
    Doi: 10.5281/zenodo.3366160
    Link: https://zenodo.org/deposit/3366160
    Description: Supplementary Material, “PLA2 inhibitor Varespladib as an alternative to the antivenom treatment for bites from Nikolsky’s viper Vipera berus nikolskii” Table 1, Necropsy results of experimental animals
MDPI and ACS Style

Zinenko, O.; Tovstukha, I.; Korniyenko, Y. PLA2 Inhibitor Varespladib as an Alternative to the Antivenom Treatment for Bites from Nikolsky’s Viper Vipera berus nikolskii. Toxins 2020, 12, 356.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop